

Max Christoph Liebau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7417643/publications.pdf>

Version: 2024-02-01

86
papers

2,844
citations

218381

26
h-index

189595

50
g-index

107
all docs

107
docs citations

107
times ranked

4214
citing authors

#	ARTICLE	IF	CITATIONS
1	Exome Capture Reveals ZNF423 and CEP164 Mutations, Linking Renal Ciliopathies to DNA Damage Response Signaling. <i>Cell</i> , 2012, 150, 533-548.	13.5	347
2	PDZD7 is a modifier of retinal disease and a contributor to digenic Usher syndrome. <i>Journal of Clinical Investigation</i> , 2010, 120, 1812-1823.	3.9	203
3	Mutations in KIF7 link Joubert syndrome with Sonic Hedgehog signaling and microtubule dynamics. <i>Journal of Clinical Investigation</i> , 2011, 121, 2662-2667.	3.9	173
4	NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway. <i>Journal of Cell Biology</i> , 2011, 193, 633-642.	2.3	142
5	Consensus Expert Recommendations for the Diagnosis and Management of Autosomal Recessive Polycystic Kidney Disease: Report of an International Conference. <i>Journal of Pediatrics</i> , 2014, 165, 611-617.	0.9	138
6	Functional expression of the renin-angiotensin system in human podocytes. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, F710-F719.	1.3	117
7	A molecular mechanism explaining albuminuria in kidney disease. <i>Nature Metabolism</i> , 2020, 2, 461-474.	5.1	99
8	Dysregulated Autophagy Contributes to Podocyte Damage in Fabry's Disease. <i>PLoS ONE</i> , 2013, 8, e63506.	1.1	97
9	A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome. <i>Kidney International</i> , 2020, 97, 1275-1286.	2.6	94
10	International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people. <i>Nature Reviews Nephrology</i> , 2019, 15, 713-726.	4.1	86
11	Imaging of Kidney Cysts and Cystic Kidney Diseases in Children: An International Working Group Consensus Statement. <i>Radiology</i> , 2019, 290, 769-782.	3.6	69
12	Perinatal Diagnosis, Management, and Follow-up of Cystic Renal Diseases. <i>JAMA Pediatrics</i> , 2018, 172, 74.	3.3	64
13	AATF/Che-1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosis. <i>EMBO Journal</i> , 2012, 31, 3961-3975.	3.5	53
14	Clinical courses and complications of young adults with Autosomal Recessive Polycystic Kidney Disease (ARPKD). <i>Scientific Reports</i> , 2019, 9, 7919.	1.6	50
15	The Ciliary Protein Nephrocystin-4 Translocates the Canonical Wnt Regulator Jade-1 to the Nucleus to Negatively Regulate β^2 -Catenin Signaling. <i>Journal of Biological Chemistry</i> , 2012, 287, 25370-25380.	1.6	49
16	Single-nephron proteomes connect morphology and function in proteinuric kidney disease. <i>Kidney International</i> , 2018, 93, 1308-1319.	2.6	49
17	Rationale, design and objectives of ARegPKD, a European ARPKD registry study. <i>BMC Nephrology</i> , 2015, 16, 22.	0.8	46
18	The Centrosomal Kinase Plk1 Localizes to the Transition Zone of Primary Cilia and Induces Phosphorylation of Nephrocystin-1. <i>PLoS ONE</i> , 2012, 7, e38838.	1.1	44

#	ARTICLE	IF	CITATIONS
19	Low levels of urinary epidermal growth factor predict chronic kidney disease progression in children. <i>Kidney International</i> , 2019, 96, 214-221.	2.6	43
20	Mycophenolate Mofetil Therapy in Children With Idiopathic Nephrotic Syndrome. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 274-279.	1.0	41
21	Risk Factors for Early Dialysis Dependency in Autosomal Recessive Polycystic Kidney Disease. <i>Journal of Pediatrics</i> , 2018, 199, 22-28.e6.	0.9	39
22	Refining genotype-phenotype correlations in 304 patients with autosomal recessive polycystic kidney disease and PKHD1 gene variants. <i>Kidney International</i> , 2021, 100, 650-659.	2.6	38
23	Conditional loss of kidney microRNAs results in congenital anomalies of the kidney and urinary tract (CAKUT). <i>Journal of Molecular Medicine</i> , 2013, 91, 739-748.	1.7	37
24	Ciliopathies - from rare inherited cystic kidney diseases to basic cellular function. <i>Molecular and Cellular Pediatrics</i> , 2015, 2, 8.	1.0	37
25	Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by <i>E. coli</i> O104:H4. <i>Clinical Infectious Diseases</i> , 2017, 64, 1637-1643.	2.9	35
26	Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease. <i>Pediatric Nephrology</i> , 2013, 28, 1771-1783.	0.9	33
27	Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling. <i>Cellular Physiology and Biochemistry</i> , 2019, 52, 1139-1150.	1.1	28
28	Definition, diagnosis and management of fetal lower urinary tract obstruction: consensus of the ERKNet CAKUT-Obstructive Uropathy Work Group. <i>Nature Reviews Urology</i> , 2022, 19, 295-303.	1.9	27
29	Mycophenolate mofetil following glucocorticoid treatment in Henoch-Schönlein purpura nephritis: the role of early initiation and therapeutic drug monitoring. <i>Pediatric Nephrology</i> , 2018, 33, 619-629.	0.9	24
30	mTOR-Activating Mutations in Rragd Are Causative for Kidney Tubulopathy and Cardiomyopathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2885-2899.	3.0	24
31	Molecular causes of congenital anomalies of the kidney and urinary tract (CAKUT). <i>Molecular and Cellular Pediatrics</i> , 2021, 8, 2.	1.0	23
32	Nephrocystin-4 Regulates Pyk2-induced Tyrosine Phosphorylation of Nephrocystin-1 to Control Targeting to Monocilia. <i>Journal of Biological Chemistry</i> , 2011, 286, 14237-14245.	1.6	22
33	Protection of Human Podocytes from Shiga Toxin 2-Induced Phosphorylation of Mitogen-Activated Protein Kinases and Apoptosis by Human Serum Amyloid P Component. <i>Infection and Immunity</i> , 2014, 82, 1872-1879.	1.0	22
34	Targeted deletion of the AAA-ATPase Ruvbl1 in mice disrupts ciliary integrity and causes renal disease and hydrocephalus. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-17.	3.2	22
35	Clinicians' attitude towards family planning and timing of diagnosis in autosomal dominant polycystic kidney disease. <i>PLoS ONE</i> , 2017, 12, e0185779.	1.1	21
36	ADPedKD: A Global Online Platform on the Management of Children With ADPKD. <i>Kidney International Reports</i> , 2019, 4, 1271-1284.	0.4	20

#	ARTICLE	IF	CITATIONS
37	Dealing with the incidental finding of secondary variants by the example of SRNS patients undergoing targeted next-generation sequencing. <i>Pediatric Nephrology</i> , 2016, 31, 73-81.	0.9	19
38	Disorders of fatty acid oxidation and autosomal recessive polycystic kidney disease—different clinical entities and comparable perinatal renal abnormalities. <i>Pediatric Nephrology</i> , 2017, 32, 791-800.	0.9	19
39	Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?. <i>Pediatric Nephrology</i> , 2018, 33, 395-408.	0.9	19
40	Network for Early Onset Cystic Kidney Diseases—A Comprehensive Multidisciplinary Approach to Hereditary Cystic Kidney Diseases in Childhood. <i>Frontiers in Pediatrics</i> , 2018, 6, 24.	0.9	19
41	Upregulation of Id-1 via BMP-2 receptors induces reactive oxygen species in podocytes. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, F654-F662.	1.3	18
42	STAT signaling in polycystic kidney disease. <i>Cellular Signalling</i> , 2020, 72, 109639.	1.7	17
43	Altered molecular signatures during kidney development after intrauterine growth restriction of different origins. <i>Journal of Molecular Medicine</i> , 2020, 98, 395-407.	1.7	17
44	Challenges in establishing genotype–phenotype correlations in ARPKD: case report on a toddler with two severe PKHD1 mutations. <i>Pediatric Nephrology</i> , 2017, 32, 1269-1273.	0.9	16
45	Unmet needs and challenges for follow-up and treatment of autosomal dominant polycystic kidney disease: the paediatric perspective. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, i14-i26.	1.4	16
46	Gastrostomy Tube Insertion in Pediatric Patients With Autosomal Recessive Polycystic Kidney Disease (ARPKD): Current Practice. <i>Frontiers in Pediatrics</i> , 2018, 6, 164.	0.9	16
47	Recent Progress of the ARegPKD Registry Study on Autosomal Recessive Polycystic Kidney Disease. <i>Frontiers in Pediatrics</i> , 2017, 5, 18.	0.9	15
48	Severe neurological outcomes after very early bilateral nephrectomies in patients with autosomal recessive polycystic kidney disease (ARPKD). <i>Scientific Reports</i> , 2020, 10, 16025.	1.6	14
49	Early clinical management of autosomal recessive polycystic kidney disease. <i>Pediatric Nephrology</i> , 2021, 36, 3561-3570.	0.9	14
50	IL-6/Smad2 signaling mediates acute kidney injury and regeneration in a murine model of neonatal hyperoxia. <i>FASEB Journal</i> , 2019, 33, 5887-5902.	0.2	13
51	Bicarbonate buffered peritoneal dialysis fluid upregulates angiotensin-1 and promotes vessel maturation. <i>PLoS ONE</i> , 2017, 12, e0189903.	1.1	13
52	Dominant SCN2A Mutation Causes Familial Episodic Ataxia and Impairment of Speech Development. <i>Neuropediatrics</i> , 2018, 49, 379-384.	0.3	12
53	Metabolic Changes in Polycystic Kidney Disease as a Potential Target for Systemic Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6093.	1.8	12
54	Early childhood height-adjusted total kidney volume as a risk marker of kidney survival in ARPKD. <i>Scientific Reports</i> , 2021, 11, 21677.	1.6	12

#	ARTICLE	IF	CITATIONS
55	The carboxyâ€terminus of the human ARPKD protein fibrocystin can control STAT3 signalling by regulating SRCâ€activation. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 14633-14638.	1.6	10
56	L1CAM mutation in a boy with hydrocephalus and duplex kidneys. <i>Pediatric Nephrology</i> , 2007, 22, 1058-1061.	0.9	9
57	An Emerging Molecular Understanding and Novel Targeted Treatment Approaches in Pediatric Kidney Diseases. <i>Frontiers in Pediatrics</i> , 2014, 2, 68.	0.9	9
58	Maintenance Peritoneal Dialysis in Children With Autosomal Recessive Polycystic Kidney Disease: A Comparative Cohort Study of the International Pediatric Peritoneal Dialysis Network Registry. <i>American Journal of Kidney Diseases</i> , 2020, 75, 460-464.	2.1	8
59	Phenotypic Variability in Siblings With Autosomal Recessive Polycystic Kidney Disease. <i>Kidney International Reports</i> , 2022, 7, 1643-1652.	0.4	6
60	Definition, diagnosis and clinical management of non-obstructive kidney dysplasia: a consensus statement by the ERKNet Working Group on Kidney Malformations. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2351-2362.	0.4	6
61	A case report on the exceptional coincidence of two inherited renal disorders: ADPKD and Alport syndrome. <i>Clinical Nephrology</i> , 2017, 88, 45-51.	0.4	5
62	A defect in molybdenum cofactor binding causes an attenuated form of sulfite oxidase deficiency. <i>Journal of Inherited Metabolic Disease</i> , 2022, 45, 169-182.	1.7	5
63	Primary URECs: a source to better understand the pathology of renal tubular epithelia in pediatric hereditary cystic kidney diseases. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 122.	1.2	5
64	Targeted deletion of <i>Ruvbl1</i> results in severe defects of epidermal development and perinatal mortality. <i>Molecular and Cellular Pediatrics</i> , 2021, 8, 1.	1.0	3
65	Systematic review on outcomes used in clinical research on autosomal recessive polycystic kidney diseaseâ€are patient-centered outcomes our blind spot?. <i>Pediatric Nephrology</i> , 2021, 36, 3841-3851.	0.9	3
66	PDZD7 is a modifier of retinal disease and a contributor to digenic Usher syndrome. <i>Journal of Clinical Investigation</i> , 2011, 121, 821-821.	3.9	3
67	Occurrence of Portal Hypertension and Its Clinical Course in Patients With Molecularly Confirmed Autosomal Recessive Polycystic Kidney Disease (ARPKD). <i>Frontiers in Pediatrics</i> , 2020, 8, 591379.	0.9	2
68	Toxigenic <i>Corynebacterium diphtheriae</i> â€Associated Genital Ulceration. <i>Emerging Infectious Diseases</i> , 2020, 26, 2180-2181.	2.0	2
69	Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial. <i>Scientific Reports</i> , 2020, 10, 4294.	1.6	2
70	Polycystic Kidney Disease: ADPKD and ARPKD. , 2016, , 333-367.		2
71	Aktuelle Forschung auf dem Gebiet der seltenen Nierenerkrankungen am Beispiel der Autosomal Rezessiven Polyzystischen Nierenerkrankung. <i>Nieren- Und Hochdruckkrankheiten</i> , 2016, 45, 425-431.	0.0	2
72	Translational research approaches to study pediatric polycystic kidney disease. <i>Molecular and Cellular Pediatrics</i> , 2021, 8, 20.	1.0	2

#	ARTICLE	IF	CITATIONS
73	Quiz Page December 2016. American Journal of Kidney Diseases, 2016, 68, A18-A21.	2.1	1
74	Editorial: Genetic Kidney Diseases of Childhood. Frontiers in Pediatrics, 2018, 6, 409.	0.9	1
75	Autosomal Recessive Polycystic Kidney Diseases. , 2021, , 1-16.		1
76	Is There a Functional Role of Mitochondrial Dysfunction in the Pathogenesis of ARPKD?. Frontiers in Medicine, 2021, 8, 739534.	1.2	1
77	Erbliche Zystennierenerkrankungen: Autosomal-dominante und autosomal-rezessive polyzystische Nierenerkrankung (ADPKD und ARPKD). Medizinische Genetik, 2018, 30, 422-428.	0.1	0
78	FP775CHILDREN WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (FH) ON LIPOPROTEIN APHERESIS á A FOUR YEAR FOLLOWá UP. Nephrology Dialysis Transplantation, 2018, 33, i306-i307.	0.4	0
79	ATRT-07. TARGETING PRIMARY CILIOGENESIS IN ATYPICAL TERATOID/RHABDOID TUMORS. Neuro-Oncology, 2019, 21, ii64-ii64.	0.6	0
80	Arterial Hypertension in a 10-Year-Old Girl. American Journal of Kidney Diseases, 2021, 77, A11-A13.	2.1	0
81	MO1005ADPKD: A GLOBAL ONLINE PLATFORM TO EXPLORE THE CHILDHOOD PHENOTYPE OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE*. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
82	MO001THE EUROPEAN DRTA REGISTRY: AN INITIAL DATA ANALYSIS*. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
83	Atypical Alport syndrome associated with a novel COL4A5 mutation. Clinical Nephrology, 2009, 71, 321-325.	0.4	0
84	Algorithmen zu syndromalen und ziliären Erkrankungen. , 2017, , 299-301.		0
85	Syndromale und ziliäre Erkrankungen1. , 2017, , 151-167.		0
86	Autosomal Recessive Polycystic Kidney Disease. , 2022, , 1-16.		0